Relationship between the EQ-5D index and measures of clinical outcomes in selected studies of cardiovascular interventions

Health and Quality of Life Outcomes

Volumn 7, Issue , 2009, Pages

  Goldsmith, Kimberley A ^a,b,c   Dyer, Matthew T ^d,e   Schofield, Peter M ^a   Buxton, Martin J ^d   Sharples, Linda D ^a,b  

^a PAPWORTH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d BRUNEL UNIVERSITY   (United Kingdom)

^e ROYAL COLLEGE OF PSYCHIATRISTS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; ADULT; ARTICLE; CANADIAN CARDIOVASCULAR SOCIETY ANGINA SEVERITY CLASS; CARDIOVASCULAR DISEASE; CLINICAL ASSESSMENT; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY RECANALIZATION; DEFIBRILLATION; DISEASE SEVERITY; EUROQOL 5D; EXERCISE TREADMILL TIME; FEMALE; HEART ASSIST DEVICE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; QUESTIONNAIRE; RATING SCALE; SCALES OF THE SEATTLE ANGINA QUESTIONNAIRE; SCORING SYSTEM; SEX DIFFERENCE; SPINAL CORD STIMULATION; AGED; ANGINA PECTORIS; CLASSIFICATION; DAILY LIFE ACTIVITY; EXERCISE TEST; HOSPITALIZATION; MIDDLE AGED; OUTCOME ASSESSMENT; SICKNESS IMPACT PROFILE; STATISTICAL MODEL;

ACTIVITIES OF DAILY LIVING; AGED; ANGINA PECTORIS; CARDIOVASCULAR DISEASES; EXERCISE TEST; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SICKNESS IMPACT PROFILE;

EID: 71949093459     PISSN: None     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/1477-7525-7-96     Document Type: Article

References (45)

1. Griffin SC, Barber JA, Manca A, Sculpher MJ, Thompson SG, Buxton MJ, Hemingway H. Cost effectiveness of clinically appropriate decisions on alternative treatments for angina pectoris: prospective observational study. BMJ 2007, 334:624. 10.1136/bmj.39129.442164.55, 1832000, 17339236.
2. Kim MC, Kini A, Sharma SK. Refractory angina pectoris: mechanism and therapeutic options. J Am Coll Cardiol 2002, 39:923-934. 10.1016/S0735-1097(02)01716-3, 11897431.
3. Sharples LD, Dyer M, Cafferty F, Demiris N, Freeman C, Banner NR, Large SR, Tsui S, Caine N, Buxton M. Cost-effectiveness of ventricular assist device use in the United Kingdom: results from the evaluation of ventricular assist device programme in the UK (EVAD-UK). J Heart Lung Transplant 2006, 25:1336-1343. 10.1016/j.healun.2006.09.011, 17097498.
4. EuroQol Group EuroQol--a new facility for the measurement of health-related quality of life. 1990, 16:199-208. The EuroQol Group. Health Policy.
5. The EQ-5D. , http://www.euroqol.org/
6. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001, 33:337-343. 10.3109/07853890109002087, 11491192.
7. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997, 35:1095-1108. 10.1097/00005650-199711000-00002, 9366889.
8. Kind P, Hardman G, Macran S. UK Population Norms for EQ-5D: York Centre for Health Economics Discussion Paper 172. 1999, , http://www.york.ac.uk/inst/che/pdf/DP172.pdf
9. Guide to the methods of technology appraisal, National Institute for Health and Clinical Excellence website. 2004, , http://www.nice.org.uk/niceMedia/pdf/TAP_Methods.pdf
10. Campbell HE, Tait S, Buxton MJ, Sharples LD, Caine N, Schofield PM, Wallwork J. A UK trial-based cost--utility analysis of transmyocardial laser revascularization compared to continued medical therapy for treatment of refractory angina pectoris. Eur J Cardiothorac Surg 2001, 20:312-318. 10.1016/S1010-7940(01)00801-6, 11463549.
11. Campbell HE, Tait S, Sharples LD, Caine N, Gray TJ, Schofield PM, Buxton MJ. Trial-based cost-utility comparison of percutaneous myocardial laser revascularisation and continued medical therapy for treatment of refractory angina pectoris. Eur J Health Econ 2005, 6:288-297. 10.1007/s10198-005-0310-5, 16195897.
12. Sharples L, Hughes V, Crean A, Dyer M, Buxton M, Goldsmith K, Stone D. Cost-effectiveness of functional cardiac testing in the diagnosis and management of coronary artery disease: a randomised controlled trial. The CECaT trial. Health Technol Assess 2007, 11:iii-115.
13. Bosch JL, Hunink MG. Comparison of the Health Utilities Index Mark 3 (HUI3) and the EuroQol EQ-5D in patients treated for intermittent claudication. Qual Life Res 2000, 9:591-601. 10.1023/A:1008929129537, 11236850.
14. de Vries M, Ouwendijk R, Kessels AG, de Haan MW, Flobbe K, Hunink MG, van Engelshoven JM, Nelemans PJ. Comparison of generic and disease-specific questionnaires for the assessment of quality of life in patients with peripheral arterial disease. J Vasc Surg 2005, 41:261-268. 10.1016/j.jvs.2004.11.022, 15768008.
15. Ellis JJ, Eagle KA, Kline-Rogers EM, Erickson SR. Validation of the EQ-5D in patients with a history of acute coronary syndrome. Curr Med Res Opin 2005, 21:1209-1216. 10.1185/030079905X56349, 16083530.
16. Eurich DT, Johnson JA, Reid KJ, Spertus JA. Assessing responsiveness of generic and specific health related quality of life measures in heart failure. Health Qual Life Outcomes 2006, 4:89. 10.1186/1477-7525-4-89, 1675990, 17125512.
17. Nowels D, McGloin J, Westfall JM, Holcomb S. Validation of the EQ-5D quality of life instrument in patients after myocardial infarction. Qual Life Res 2005, 14:95-105. 10.1007/s11136-004-0614-4, 15789944.
18. Schweikert B, Hahmann H, Leidl R. Validation of the EuroQol questionnaire in cardiac rehabilitation. Heart 2006, 92:62-67. 10.1136/hrt.2004.052787, 1860985, 15797936.
19. Spertus J, Peterson E, Conard MW, Heidenreich PA, Krumholz HM, Jones P, McCullough PA, Pina I, Tooley J, Weintraub WS, Rumsfeld JS. Monitoring clinical changes in patients with heart failure: a comparison of methods. Am Heart J 2005, 150:707-715. 10.1016/j.ahj.2004.12.010, 16209970.
20. van Stel HF, Buskens E. Comparison of the SF-6D and the EQ-5D in patients with coronary heart disease. Health Qual Life Outcomes 2006, 4:20. 10.1186/1477-7525-4-20, 1475841, 16563170.
21. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002, 21:271-292. 10.1016/S0167-6296(01)00130-8, 11939242.
22. Brazier J, Roberts J, Tsuchiya A, Busschbach J. A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ 2004, 13:873-884. 10.1002/hec.866, 15362179.
23. Bruce RA, McDonough JR. Stress testing in screening for cardiovascular disease. Bull N Y Acad Med 1969, 45:1288-1305. 1750554, 5261245.
24. Campeau L. Letter: Grading of angina pectoris. Circulation 1976, 54:522-523.
25. The Criteria Committee of the New York Heart Association Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 1994, 253-256. Boston, MA: Little, Brown & Co, 9.
26. Spertus JA, Winder JA, Dewhurst TA, Deyo RA, Prodzinski J, McDonell M, Fihn SD. Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease. J Am Coll Cardiol 1995, 25:333-341. 10.1016/0735-1097(94)00397-9, 7829785.
27. Norris CM, Ghali WA, Saunders LD, Brant R, Galbraith PD. Systematic review of statistical methods used to analyze Seattle Angina Questionnaire scores. Can J Cardiol 2004, 20:187-193.
28. Buxton M, Caine N, Chase D, Connelly D, Grace A, Jackson C, Parkes J, Sharples L. A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context. Health Technol Assess 2006, 10:iii-xi. 16904046.
29. Gray TJ, Burns SM, Clarke SC, Tait S, Sharples LD, Caine N, Schofield PM. Percutaneous myocardial laser revascularization in patients with refractory angina pectoris. Am J Cardiol 2003, 91:661-666. 10.1016/S0002-9149(02)03303-9, 12633794.
30. Schofield PM, Sharples LD, Caine N, Burns S, Tait S, Wistow T, Buxton M, Wallwork J. Transmyocardial laser revascularisation in patients with refractory angina: a randomised controlled trial. Lancet 1999, 353:519-524. 10.1016/S0140-6736(98)11478-2, 10028979.
31. McNab D, Khan SN, Sharples LD, Ryan JY, Freeman C, Caine N, Tait S, Hardy I, Schofield PM. An open label, single-centre, randomized trial of spinal cord stimulation vs. percutaneous myocardial laser revascularization in patients with refractory angina pectoris: the SPiRiT trial. Eur Heart J 2006, 27:1048-1053. 10.1093/eurheartj/ehi827, 16554313.
32. Pinheiro JC, Bates DM. Mixed-Effects Models in S and S-plus. 2000, New York, NY: Springer.
33. Dolan P, Gudex C, Kind P, Williams A. The time trade-off method: results from a general population study. Health Econ 1996, 5:141-154. 10.1002/(SICI)1099-1050(199603)5:2<141::AID-HEC189>3.0.CO;2-N, 8733106.
34. Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res 2005, 14:1523-1532. 10.1007/s11136-004-7713-0, 16110932.
35. Cochran W. The combination of estimates from different experiments. Biometrics 1954, 10:101-129.
36. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558. 10.1002/sim.1186, 12111919.
37. Badia X, Schiaffino A, Alonso J, Herdman M. Using the EuroQoI 5-D in the Catalan general population: feasibility and construct validity. Qual Life Res 1998, 7:311-322. 10.1023/A:1008894502042, 9610215.
38. Longworth L, Bryan S. An empirical comparison of EQ-5D and SF-6D in liver transplant patients. Health Econ 2003, 12:1061-1067. 10.1002/hec.787, 14673814.
39. Bahit MC, Cannon CP, Antman EM, Murphy SA, Gibson CM, McCabe CH, Braunwald E. Direct comparison of characteristics, treatment, and outcomes of patients enrolled versus patients not enrolled in a clinical trial at centers participating in the TIMI 9 Trial and TIMI 9 Registry. Am Heart J 2003, 145:109-117. 10.1067/mhj.2003.43, 12514662.
40. Hallstrom A, Friedman L, Denes P, Rizo-Patron C, Morris M. Do arrhythmia patients improve survival by participating in randomized clinical trials? Observations from the Cardiac Arrhythmia Suppression Trial (CAST)and the Antiarrhythmics Versus Implantable Defibrillators Trial (AVID). Control Clin Trials 2003, 24:341-352. 10.1016/S0197-2456(03)00002-3, 12757998.
41. Kind P, Dolan P, Gudex C, Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 1998, 316:736-741. 28477, 9529408.
42. Norris CM, Ghali WA, Galbraith PD, Graham MM, Jensen LA, Knudtson ML. Women with coronary artery disease report worse health-related quality of life outcomes compared to men. Health Qual Life Outcomes 2004, 2:21. 10.1186/1477-7525-2-21, 420257, 15128455.
43. Blomkalns AL, Chen AY, Hochman JS, Peterson ED, Trynosky K, Diercks DB, Brogan GX, Boden WE, Roe MT, Ohman EM, Gibler WB, Newby LK. Gender disparities in the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: large-scale observations from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines) National Quality Improvement Initiative. J Am Coll Cardiol 2005, 45:832-837. 10.1016/j.jacc.2004.11.055, 15766815.
44. Daly C, Clemens F, Lopez Sendon JL, Tavazzi L, Boersma E, Danchin N, Delahaye F, Gitt A, Julian D, Mulcahy D, Ruzyllo W, Thygesen K, Verheugt F, Fox KM. Gender differences in the management and clinical outcome of stable angina. Circulation 2006, 113:490-498. 10.1161/CIRCULATIONAHA.105.561647, 16449728.
45. Zareba W, Moss AJ, Jackson HW, Wilber DJ, Ruskin JN, McNitt S, Brown M, Wang H. Clinical course and implantable cardioverter defibrillator therapy in postinfarction women with severe left ventricular dysfunction. J Cardiovasc Electrophysiol 2005, 16:1265-1270.